BBOT vs. CCCC
BBOT (BridgeBio Oncology Therapeutics, Inc) and CCCC (C4 Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. At a 0.26 correlation, their price movements are largely independent.
Performance
BBOT vs. CCCC - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BBOT achieves a -33.95% return, which is significantly lower than CCCC's 127.23% return.
BBOT
- 1D
- -3.27%
- 1M
- -1.43%
- YTD
- -33.95%
- 6M
- -27.14%
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
CCCC
- 1D
- -0.91%
- 1M
- 48.63%
- YTD
- 127.23%
- 6M
- 78.60%
- 1Y
- 226.32%
- 3Y*
- 8.58%
- 5Y*
- -35.26%
- 10Y*
- —
BBOT vs. CCCC - Yearly Performance Comparison
| 2026 (YTD) | 2025 | |
|---|---|---|
BBOT BridgeBio Oncology Therapeutics, Inc | -33.95% | 29.74% |
CCCC C4 Therapeutics, Inc. | 127.23% | -14.73% |
Correlation
The correlation between BBOT and CCCC is 0.26, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (All Time) Calculated using the full available price history since Aug 13, 2025 | 0.26 |
Fundamentals
BBOT:
$661.86M
CCCC:
$547.16M
BBOT:
-$3.90
CCCC:
-$1.18
BBOT:
$0.00
CCCC:
$28.71M
BBOT:
-$194.00K
CCCC:
$26.90M
BBOT:
-$168.31M
CCCC:
-$107.31M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BBOT vs. CCCC — Risk / Return Rank
BBOT
CCCC
BBOT vs. CCCC - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for BridgeBio Oncology Therapeutics, Inc (BBOT) and C4 Therapeutics, Inc. (CCCC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Loading charts...
Sharpe Ratios by Period
| BBOT | CCCC | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | — | 2.22 | — |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | -0.30 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.25 | -0.24 | -0.01 |
Drawdowns
BBOT vs. CCCC - Drawdown Comparison
The maximum BBOT drawdown since its inception was -44.21%, smaller than the maximum CCCC drawdown of -97.82%. Use the drawdown chart below to compare losses from any high point for BBOT and CCCC.
Loading charts...
Drawdown Indicators
| BBOT | CCCC | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -44.21% | -97.82% | +53.61% |
Max Drawdown (1Y)Largest decline over 1 year | — | -52.10% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -90.00% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -97.82% | — |
Current DrawdownCurrent decline from peak | -39.77% | -91.41% | +51.64% |
Average DrawdownAverage peak-to-trough decline | -18.98% | -71.88% | +52.90% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 26.87% | — |
Volatility
BBOT vs. CCCC - Volatility Comparison
Loading charts...
Volatility by Period
| BBOT | CCCC | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | — | 28.88% | — |
Volatility (6M)Calculated over the trailing 6-month period | — | 64.86% | — |
Volatility (1Y)Calculated over the trailing 1-year period | 71.26% | 102.71% | -31.45% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 71.26% | 117.40% | -46.14% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 71.26% | 113.14% | -41.88% |
Dividends
BBOT vs. CCCC - Dividend Comparison
Neither BBOT nor CCCC has paid dividends to shareholders.
Financials
BBOT vs. CCCC - Financials Comparison
This section allows you to compare key financial metrics between BridgeBio Oncology Therapeutics, Inc and C4 Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
BBOT and CCCC have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for BBOT and CCCC
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer